TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00794625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproate
Description: Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Standard therapeutic doses of risperidone for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Standard therapeutic doses of risperidone for 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An inactive substance at identical dosing to active treatments for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Description: Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stimulant medication
Description: Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Stimulant medication
Description: Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral family counseling
Description: Weekly behavioral counseling with a therapist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral family counseling
Description: Weekly behavioral counseling with a therapist
Study: NCT03890224

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: home ventilators
Description: The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: home ventilators
Description: The 3 test treatments are home non-targeted NIV, home targeted NIV and rescue home NIV. COPD patients will be equipped with home ventilators and fitted with either nasal, oronasal or facial masks. All the ventilators used will be CE marked.
Study: NCT04397133

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inspiratory muscle training
Description: inspiratory muscle training will be done with Philips Respironics Threshold IMT device starting with resistance of % 50 of MIP value
Study: NCT02247791

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Uncemented femoral stem
Description: All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented femoral stem
Description: All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
Study: NCT00178178

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Pain Care 3000 Catheter
Description: Device: Breg Pain Care 3000 Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Pain Care 3000 Catheter
Description: Device: Breg Pain Care 3000 Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Breg Pain Care 3000 Catheter
Description: Device: Breg Pain Care 3000 Catheter

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Breg Pain Care 3000 Catheter
Description: Device: Breg Pain Care 3000 Catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5%
Description: Drug: Bupivicaine 0.5 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5%
Description: Drug: Bupivicaine 0.5 %

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine 0.5%
Description: Drug: Bupivicaine 0.5 %

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo
Study: NCT04723693

Intervention type: OTHER
Intervention: Qualitative Interview
Description: A single one hour semi structured qualitative interview
Study: NCT00761813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Open reduction internal fixation (ORIF) with single sliding hip screw
Description: The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORIF with multiple cancellous screws
Description: ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
Study: NCT01558635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioblate CryoFlex Surgical Ablation
Description: Longstanding persistent AF was treated with the Cox Cryo Maze III procedure During mitral valve surgery a surgical ablation was performed, using the Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mitral Valve surgery
Description: Classic mitral valve surgery was performed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Reveal XT Insertable Cardiac Monitor
Description: During the procedure, a Medtronic Reveal XT Insertable Cardiac Monitor was implanted to monitor episodes of AF during follow-up period

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MAZE III
Description: Longstanding persistent AF was treated with the Cox Cryo Maze III procedure
Study: NCT04953260

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: APRF
Description: 20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of APRF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of APRF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with APRF film

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CGF
Description: 20ml venous blood was collected from the elbow before operation and centrifuged with a special centrifuge. One piece of CGF gel was chopped and mixed with Bio-oss, and the other piece was pressed into a thin film; the mixture of CGF and Bio-oss was filled into the bone defect, covered with a properly trimmed Bio-gide film, and then covered with CGF film
Study: NCT02277860

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
Study: NCT03713788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Description: Participants placed their non-dominant hand into cold water for 2 minutes
Study: NCT04989738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE intervention
Description: Parents learn responsive parenting skills, such as a) recognizing infant hunger and satiety cues and using feeding more selectively in response to hunger only, b) recognizing other reasons for crying or fussy behavior and using alternative soothing strategies when these other reasons apply, c) learning to lay the foundation for healthy infant sleep and respond to nighttime awakenings to promote self-soothing, and d) learning to introduce complimentary foods at 6 months, provide repeated exposure to a variety of healthy foods using positive role modeling, and allow infants to determine the amount consumed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Parents learn about development, safety, and positive parenting without a specific emphasis on feeding, sleep, and soothing.
Study: NCT01777529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Vaccine
Description: Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
Study: NCT04397133

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: in these group the patients will get sham intervention with Philips Respironics Threshold IMT device
Study: NCT02320331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PILI Lifestyle Program
Description: A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
Study: NCT01777529

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMR Vaccine
Description: Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
Study: NCT01533155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nektar 118
Description: Oral 25 mg tablet
Study: NCT02441114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP0910 and HGP1011
Description: Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
Study: NCT03364010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of proprioception
Description: Velocity perception and Position perception

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of motor learning
Description: Motor accurancy and State Estimation with visual perturbations

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evaluation of written language
Description: Text reading, Identifying words and Phonological awareness: phonemic blending and phonemic elision
Study: NCT05012969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hipstop bandage
Description: 12 weeks use of a bandage to prevent hip dislocations in patients with previous dislocations
Study: NCT00977873

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miglyol oil
Description: Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
Study: NCT01793909

Intervention type: OTHER
Group type: OTHER
Intervention: Single Leg Exercise Training
Description: Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
Study: NCT00625378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: At the same dose and schedule as in the participants' original clinical trials
Study: NCT01533155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nektar 118
Description: Oral 25 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nektar 118
Description: Oral 25 mg tablet
Study: NCT03270241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet
Description: This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
Study: NCT02403037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True auricular acupressure
Description: A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham auricular acupressure
Description: A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
Description: 5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
Description: 5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)
Description: 5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
Study: NCT03921437

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: decision support intervention
Description: CKD Guardian is the decision-maker and uses the e-book software to develop medical decision-assist tools, and applies this tool and decision-directed mode to introduce and select. The implementation steps include team discussion, option discussion and decision-making. The group is introduced with traditional care instructions for routine care.
Study: NCT01544075

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neurophysiology education (PNE) and psychologic inoculation (PI)
Description: 3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neck school (NS)
Description: 3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
Study: NCT03391323

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK Sphere® Medial-Pivot Knee Prosthesis

Intervention type: DEVICE
Group type: OTHER
Intervention: Medacta GMK PS Posterior Stabilized Knee Prosthesis
Study: NCT02898831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Compress
Description: Cold Compress placed on lower abdomen prior to and during IUD insertion.
Study: NCT02852434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Gel (2%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Paracervical Block (1%)
Study: NCT03188705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
Study: NCT02018887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2969822
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2969822
Description: Capsules administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2969822
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study: NCT04116047

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study: NCT04179149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental enrichment
Description: The experimental group will participate in six modules that mimic and integrate the three hallmarks of EE: social interaction (more animals per cage = support group meetings, online support), novelty (toys and activities = exposure to new hands-on activities), and larger enclosures (larger cages = meetings in open environments). There will be 2 interventions per month, for three months, and a follow up 3 months after the end of the intervention
Study: NCT04738162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminolevulinic Acid Hydrochloride, Oral
Description: Application of 5-ALA oral solution (20mg/kg bw) 4 hours (range 3.5-4.5 hours) prior to anesthesia followed by fluorescence-guided tumor resection Tumor resection is performed conventionally using a surgical microscope. A change from white light to blue light is possible at anytime to make the fluorescence visible
Study: NCT03581747

Intervention type: DEVICE
Intervention: Nevisense
Description: Measurement of electrical impedance

Intervention type: DEVICE
Intervention: Nevisense
Description: Measurement of electrical impedance
Study: NCT03279965

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
Study: NCT01197898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Collagenase Santyl Ointment
Description: Topical daily application

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Topical daily application
Study: NCT03968627

Intervention type: OTHER
Intervention: Rehabilitative intervention
Description: intensive multidisciplinar rehabilitation
Study: NCT03061851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional treatment
Description: the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltose app
Description: 1. Weekly diabetes-related science articles.~2. Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.~3. Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.~4. monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.~5. Personalize the development of diet, exercise program.~6. different insulin and oral hypoglycemic drug medication time to remind.~7. hypoglycemic drug side effects query.
Study: NCT01533155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nektar 118
Description: Oral 25 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinidine
Description: Oral 200 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinidine
Description: Oral 200 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Quinidine placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinidine placebo
Description: Oral Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Morphine
Description: 10 mg/ml, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 10 mg/ml, intravenously
Study: NCT00565422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 mg/day
Study: NCT01561131

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 45g protein/d; Dosage 3x15g protein daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein enriched with calcium
Description: 45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy protein
Description: 45g soy protein/d; dosage 15g soy protein x 3 daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: 48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
Study: NCT00989703

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral solution, daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG0259
Description: oral solution
Study: NCT00290758

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04091308

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care involves physiotherapeutic rehabilitation in an unknown format, and will, therefore, be monitored closely and described accordingly.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care with Protein Supplementation
Description: The intake of protein supplementation (ARLA PROTINO) will be consumed by participants in the form of protein-enriched yogurts for easy consumption two times daily, with each bottle containing 14 g of protein.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Physical Exercise Training with Protein Supplementation
Description: Besides getting prescribed individualized physical exercise training programs, this group will consume protein supplementation (ARLA PROTINO) in form of protein enriched yogurts for easy consumption, two times daily, with each bottle containing 14 g of protein.